PRESS
      PR PharmaResearch Acquires TURINGBIO, a Digital Healthcare Solution Company
      2024. 07. 10

      PharmaResearch Acquires TURINGBIO, a Digital Healthcare Solution Company

       

      Securing the ability to develop AI solutions ... to lead the way globally in aesthetic and medical innovation


       

       

      PharmaResearch (CEOs: Ki Seock Kang, ThinKyou Kim), a biopharmaceutical company, announced that it has acquired TURINGBIO (CEO: Michael Shim), an AI-based digital healthcare solution company.

       

      This acquisition is expected to give PharmaResearch access to highly qualified developers in the field of Digital Therapeutics (DTx), as well as the ability to apply AI technology to the aesthetics and medical business to further advance its expertise and capabilities in the market.

       

      As an AI-based digital healthcare solution company founded in 2020, TURINGBIO has developed and supplied a range of products, including DepRx®, an evidence-based digital treatment device for depression, WeeDool®, a personalized comprehensive psychological counseling platform using generative AI, and VitalTracker®, a digital phenotype data tracking and prediction system for quantitative diagnosis of mental illness.

       

      We decided to make this acquisition as digital transformation is increasingly required in the pharmaceutical and bio industries, said ThinKyou Kim, CEO of PharmaResearch. TURINGBIO’s excellent AI solution capabilities will help us accelerate DTx-related research and development and lead innovative technologies in aesthetics and medicine globally through synergies with our existing businesses.

       

      This collaboration is a significant leap forward for us, said a TURINGBIO official, Combining PharmaResearch’s regenerative medicine expertise and infrastructure with TURINGBIO’s generative AI digital health technology will help us develop more innovative and customized solutions.

       

      ParmarResearch is a regenerative medicine-based bio-pharma company that produces and sells pharmaceuticals, medical devices, cosmetics, and health supplements based on its tissue regeneration technologies DOTPDRN and DOTPN. The company offers a range of products, including REJURAN®, REJUVIEL®, CONJURAN®, REJURAN Cosmetics, and Re-An® Eye Drops, REJUDERMA®, and REJUVENEX® Cream.